Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 5Not yet recruiting 4Unknown 2Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 7Stomach Neoplasms 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Hodgkin Disease 2Glioblastoma 2mCRPC 1Uterine Cervical Neoplasms 1Unresectable Stage III Non-small Cell Lung Cancer 1Tongue Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Rare Tumour 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1MSI-H Colorectal Cancer 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Capecitabine 13Oxaliplatin 10Radiotherapy 8Surgical Procedures, Operative 6Drug Therapy 5tislelizumab 4Irinotecan 4sintilimab 3Neoadjuvant Therapy 3Immunotherapy 3Fluorouracil 3Endoscopic Mucosal Resection 3Bevacizumab 3spartalizumab 2raltitrexed 2XELOX 2Trinitrotoluene 2Radiation 2Immune Checkpoint Inhibitors 2Folfox protocol 2Cetuximab 2toripalimab 1sperm releasing substance 1saxagliptin 1s-formylglutathione hydrolase 1envafolimab 1disitamab vedotin 1cemiplimab 1camrelizumab 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Rectal Neoplasms × tislelizumab × Clear all
NCT06504875 2024-07-17

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting
23 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06390982 2024-04-30

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Fudan University

Phase 2 Not yet recruiting
46 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05507112 2022-09-21

TIMENT-R

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
100 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04443543 2020-06-30

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Fudan University

Phase 2 Not yet recruiting
222 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡